Clinical trial
Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately…
NCT00329225 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00329225 |
|---|---|
| Title | Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin |
| Official title | A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Control, Clinical Evaluation of Insulin Plus Rosiglitazone (2mg and 4mg) Compared to Insulin Plus Placebo for 24 Weeks in Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled on Insulin |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | rosiglitazone |
| Enrollment | 630 |
| Start date | Sep 1, 2002 |
| Primary completion | Apr 1, 2004 |
| Completion | Apr 1, 2004 |
| First posted | May 24, 2006 |
| Last update posted | Sep 15, 2016 |
| Countries | United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: